Papers

1

Total Citations

28

H-Index

1

About

Radim Nencka is a leading figure in chemical biology and medicinal chemistry, whose research focuses on the discovery and mechanistic characterization of small-molecule inhibitors targeting lipid kinases and viral enzymes. His major contributions center on phosphatidylinositol 4-kinases (PI4Ks), key regulators of lipid transfer and membrane dynamics. Notably, his 2019 study, which has garnered 28 citations, describes a large-scale high-throughput screen that identified chemical inhibitors of PI4K type II alpha, advancing our understanding of PI4P’s role in ER-membrane contact sites and cellular signaling. This work underscores his impact in unraveling the complex biology of minor phospholipids. Beyond lipid kinases, Nencka has made significant strides in antiviral drug development, particularly against hepatitis C virus and SARS-CoV-2, where his team’s innovative nucleoside analogs have shown promise. With a publication record that consistently draws attention from the scientific community, his research bridges fundamental biochemistry and translational medicine, offering tools to probe lipid signaling and potential therapeutic leads. His achievements highlight a career dedicated to chemical probe development and the pursuit of novel drug targets.

Research Focus

Key Achievements

1
H-Index
1
Papers
28
Total Citations
28
Avg Citations/Paper
🏆 Most Cited Paper
A large scale high-throughput screen identifies chemical inhibitors of phosphatidylinositol 4-kinase type II alpha
28 citations · 2019
📈 Most Prolific Year: 2019 (1 Papers)
🤝 Key Collaborators: 14
🏛 Institutions: Czech Academy of Sciences, Institute of Organic Chemistry and Biochemistry

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago